Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 42.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 160,324 shares of the medical equipment provider's stock after selling 118,465 shares during the quarter. Calamos Advisors LLC owned about 0.08% of Zimmer Biomet worth $18,145,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Garde Capital Inc. bought a new position in shares of Zimmer Biomet in the first quarter worth about $29,000. Menard Financial Group LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $30,000. Washington Trust Advisors Inc. bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $30,000. Accredited Wealth Management LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $36,000. Finally, OFI Invest Asset Management acquired a new position in Zimmer Biomet during the 4th quarter valued at approximately $40,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.70% of the company's stock.

Zimmer Biomet Trading Up 1.0%

NYSE ZBH traded up $0.89 on Tuesday, reaching $93.46. The stock had a trading volume of 1,502,714 shares, compared to its average volume of 1,811,538. The firm has a market capitalization of $18.49 billion, a price-to-earnings ratio of 20.68, a P/E/G ratio of 2.14 and a beta of 0.71. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $116.71. The stock has a fifty day moving average price of $93.67 and a two-hundred day moving average price of $101.57.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The firm had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the previous year, the company earned $1.94 earnings per share. Zimmer Biomet's quarterly revenue was up 1.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a $0.24 dividend. The ex-dividend date is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.03%. Zimmer Biomet's payout ratio is 21.24%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Evercore ISI lowered their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research note on Tuesday. Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the stock a "buy" rating in a research note on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Wells Fargo & Company lowered their price objective on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $110.56.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.